Paramasari Dirgahayu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Paramasari Dirgahayu has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Eti Poncorini Pamungkasari
Universitas Sebelas Maret
7 shared publications - Risya Cilmiaty
Universitas Sebelas Maret, Surakarta, Indonesia
6 shared publications - Adi Prayitno
Universitas Sebelas Maret, Surakarta, Indonesia
3 shared publications Brian Wasita
3 shared publications- Brian Wasita
Doctoral Program of Medical Sciences, Faculty of Medicine, Universitas Sebelas Maret, Surakarta, Indonesia
3 shared publications - Ida Nurwati
Universitas Sebelas Maret
3 shared publications
Latest Publications
- Open Access
- 11 March 2026
- Published by Pandawa Institute in Journal of Multidisciplinary Applied Natural Science
- Vol. 6 (2) , 983-997
Modulation of AR-FGF-2-TGF beta Axis by Cosmos caudatus Suppresses Prostatic Epithelial Proliferation in a BPH Rat Model: A Comparative Study with Finasteride
Benign prostatic hyperplasia (BPH) progression is critically influenced by the androgen receptor (AR), Fibroblast growth factor-2 (FGF-2), and transforming growth factor-β (TGF-β) signaling axis. Although finasteride (FIN) is the standard therapeutic agent, its use is limited by adverse effects. This study evaluated the efficacy of Cosmos caudatus (CC) extract, administered alone or in combination with FIN, in modulating the AR–FGF-2–TGF-β axis in a testosterone-induced BPH rat model. Rats were divided into five groups (n = 6): Normal (N), BPH control (KN), FIN (KP; 0.44 mg/kg), CC extract (P1; 250 mg/kg), and combination (P2; CC 250 mg/kg + FIN 0.44 mg/kg). Prostatic AR, FGF-2, and TGF-β expression was analyzed using immunohistochemistry (IHC) with H-score quantification. Both KP and P1 significantly reduced AR (KP: 112 ± 15; P1: 105 ± 12 vs KN: 195 ± 18, p < 0.05) and FGF-2 (KP: 98 ± 14; P1: 92 ± 11 vs KN: 180 ± 20, p < 0.05), approaching normal values (AR N: 90 ± 10; FGF-2 N: 85 ± 9). In contrast, combination therapy (P2) failed to suppress AR (188 ± 17, p = 0.936) and FGF-2 (175 ± 19, p = 0.870) and induced a significant increase in TGF-β (P2: 145 ± 16 vs KN: 110 ± 12, p < 0.05). All treatment groups showed reduced epithelial thickness and prostate index (p < 0.05). These findings indicate that CC extract alone exerts therapeutic effects comparable to FIN by modulating the AR–FGF-2 axis, whereas combining it with FIN disrupts pathway regulation and promotes a pro-fibrotic response. The study supports the potential of CC extract as an effective alternative for BPH management without pharmacologic complications.
- 11 March 2026
- Published by Pandawa Institute in Journal of Multidisciplinary Applied Natural Science
- Vol. 6 (2) , 983-997
Open AccessModulation of AR-FGF-2-TGF beta Axis by Cosmos caudatus Suppresses Prostatic Epithelial Proliferation in a BPH Rat Model: A Comparative Study with Finasteride
Benign prostatic hyperplasia (BPH) progression is critically influenced by the androgen receptor (AR), Fibroblast growth factor-2 (FGF-2), and transforming growth factor-β (TGF-β) signaling axis. Although finasteride (FIN) is the standard therapeutic agent, its use is limited by adverse effects. This study evaluated the efficacy of Cosmos caudatus (CC) extract, administered alone or in combination with FIN, in modulating the AR–FGF-2–TGF-β axis in a testosterone-induced BPH rat model. Rats were divided into five groups (n = 6): Normal (N), BPH control (KN), FIN (KP; 0.44 mg/kg), CC extract (P1; 250 mg/kg), and combination (P2; CC 250 mg/kg + FIN 0.44 mg/kg). Prostatic AR, FGF-2, and TGF-β expression was analyzed using immunohistochemistry (IHC) with H-score quantification. Both KP and P1 significantly reduced AR (KP: 112 ± 15; P1: 105 ± 12 vs KN: 195 ± 18, p < 0.05) and FGF-2 (KP: 98 ± 14; P1: 92 ± 11 vs KN: 180 ± 20, p < 0.05), approaching normal values (AR N: 90 ± 10; FGF-2 N: 85 ± 9). In contrast, combination therapy (P2) failed to suppress AR (188 ± 17, p = 0.936) and FGF-2 (175 ± 19, p = 0.870) and induced a significant increase in TGF-β (P2: 145 ± 16 vs KN: 110 ± 12, p < 0.05). All treatment groups showed reduced epithelial thickness and prostate index (p < 0.05). These findings indicate that CC extract alone exerts therapeutic effects comparable to FIN by modulating the AR–FGF-2 axis, whereas combining it with FIN disrupts pathway regulation and promotes a pro-fibrotic response. The study supports the potential of CC extract as an effective alternative for BPH management without pharmacologic complications.
- Open Access
- 1 March 2026
- Published by Garval Editorial Ltda. in Journal of Pharmacy & Pharmacognosy Research
- Vol. 14 (2)
Network pharmacology and molecular docking approach to identify the mechanisms and molecular targets of Allium ascalonicum L. extract against atherosclerosis
Context: Atherosclerosis remains a leading cause of mortality globally, and current therapeutic strategies are often insufficient. Allium ascalonicum L. (shallot) has demonstrated cardioprotective effects, but its molecular mechanisms remain inadequately defined. Aims: To elucidate the molecular mechanisms and potential targets of A. ascalonicum extract in the prevention and treatment of atherosclerosis. Methods: A network pharmacology and molecular docking approach was employed to investigate the interactions between key bioactive compounds (kaempferol, quercetin, quercetin 3-O-alpha-L-rhamnoside, and allicin) and atherosclerosis-associated proteins. Results: Target prediction identified 1,644 atherosclerosis-related proteins interacting with A. ascalonicum compounds. Among these, Nrf2 was highlighted as a primary target involved in lipid metabolism, oxidative stress, and inflammation. Molecular docking revealed strong binding affinities between Nrf2 regulators (KEAP1) and bioactive compounds, particularly quercetin 3-O-alpha-L-rhamnoside. Conclusions: The findings suggest that A. ascalonicum may serve as a potential anti-atherosclerotic agent through modulation of the KEAP1-Nrf2 pathway. These results warrant further experimental validation.
- 1 March 2026
- Published by Garval Editorial Ltda. in Journal of Pharmacy & Pharmacognosy Research
- Vol. 14 (2)
Open AccessNetwork pharmacology and molecular docking approach to identify the mechanisms and molecular targets of Allium ascalonicum L. extract against atherosclerosis
Context: Atherosclerosis remains a leading cause of mortality globally, and current therapeutic strategies are often insufficient. Allium ascalonicum L. (shallot) has demonstrated cardioprotective effects, but its molecular mechanisms remain inadequately defined. Aims: To elucidate the molecular mechanisms and potential targets of A. ascalonicum extract in the prevention and treatment of atherosclerosis. Methods: A network pharmacology and molecular docking approach was employed to investigate the interactions between key bioactive compounds (kaempferol, quercetin, quercetin 3-O-alpha-L-rhamnoside, and allicin) and atherosclerosis-associated proteins. Results: Target prediction identified 1,644 atherosclerosis-related proteins interacting with A. ascalonicum compounds. Among these, Nrf2 was highlighted as a primary target involved in lipid metabolism, oxidative stress, and inflammation. Molecular docking revealed strong binding affinities between Nrf2 regulators (KEAP1) and bioactive compounds, particularly quercetin 3-O-alpha-L-rhamnoside. Conclusions: The findings suggest that A. ascalonicum may serve as a potential anti-atherosclerotic agent through modulation of the KEAP1-Nrf2 pathway. These results warrant further experimental validation.
- Open Access
- 17 January 2026
- Published by Pandawa Institute in Journal of Multidisciplinary Applied Natural Science
- Vol. 6 (2) , 623-650
Caesalpinia bonduc (L) Roxb Seed Extract Dosage and Sex Effects on Pathobiological Changes in A Rat Model of Diabetes Mellitus
Caesalpinia bonduc (L) Roxb is a medicinal plant commonly utilized in traditional Indonesian medicine, particularly for the treatment of diabetes mellitus (DM). This study examined the effects of varying doses C. bonduc extract on fasting blood sugar (FBS), malondialdehyde (MDA), tumor necrosis factor-α (TNF-α), transforming growth factor-β (TGF-β), and pancreatic histology in male and female wistar rats with diabetes. The study design included six groups of 18 male and female rats (Wistar strain) each. To develop diabetes, nicotinamide (NA) (110 mg/kg) and streptozotocin (STZ) (45 mg/kg) were supplied, followed by oral administration of C. bonduc extract at dosages of 200, 400, and 600 mg/kg for 21 days. We utilized ELISA to analyze biochemical parameters and employed H&E staining to evaluate histological changes. A factorial design was employed for the statistical analysis to examine the effects of both dosage and sex. This study offers a unique comparative examination of the antidiabetic efficacy of C. bonduc across genders, a dimension seldom explored in experimental diabetes research. The findings indicated that C. bonduc markedly reduced levels of FBS, MDA, TNF-α, and TGF-β (p < 0.05) enhanced the structural integrity of the pancreas. There were no significant differences between males and female (p > 0.05). The dosage and sex influenced MDA and TGF-β. The extract of C. bonduc shown the ability to lower blood sugar, fight free radicals, and reduce inflammation; however, the intensity of these benefits depended on the dosage given. This means that it might assist persons with diabetes minimize oxidative stress and damage to the pancreas.
- 17 January 2026
- Published by Pandawa Institute in Journal of Multidisciplinary Applied Natural Science
- Vol. 6 (2) , 623-650
Open AccessCaesalpinia bonduc (L) Roxb Seed Extract Dosage and Sex Effects on Pathobiological Changes in A Rat Model of Diabetes Mellitus
Caesalpinia bonduc (L) Roxb is a medicinal plant commonly utilized in traditional Indonesian medicine, particularly for the treatment of diabetes mellitus (DM). This study examined the effects of varying doses C. bonduc extract on fasting blood sugar (FBS), malondialdehyde (MDA), tumor necrosis factor-α (TNF-α), transforming growth factor-β (TGF-β), and pancreatic histology in male and female wistar rats with diabetes. The study design included six groups of 18 male and female rats (Wistar strain) each. To develop diabetes, nicotinamide (NA) (110 mg/kg) and streptozotocin (STZ) (45 mg/kg) were supplied, followed by oral administration of C. bonduc extract at dosages of 200, 400, and 600 mg/kg for 21 days. We utilized ELISA to analyze biochemical parameters and employed H&E staining to evaluate histological changes. A factorial design was employed for the statistical analysis to examine the effects of both dosage and sex. This study offers a unique comparative examination of the antidiabetic efficacy of C. bonduc across genders, a dimension seldom explored in experimental diabetes research. The findings indicated that C. bonduc markedly reduced levels of FBS, MDA, TNF-α, and TGF-β (p < 0.05) enhanced the structural integrity of the pancreas. There were no significant differences between males and female (p > 0.05). The dosage and sex influenced MDA and TGF-β. The extract of C. bonduc shown the ability to lower blood sugar, fight free radicals, and reduce inflammation; however, the intensity of these benefits depended on the dosage given. This means that it might assist persons with diabetes minimize oxidative stress and damage to the pancreas.
- 27 December 2025
- Published by CMMB-Colegiul Medicilor Municipiul Bucuresti in Medicina Moderna - Modern Medicine
- Vol. 32 (4) , 323-332
The Effect of Moringa oleifera on Hematological Parameters in Chemotherapy-Induced Anemia: A Systematic Review and Meta-analysis
Background: Chemotherapy-induced anemia (CIA) is a common complication caused by bone marrow suppression in patients receiving chemotherapy. Standard treatments, including erythropoiesisstimulating agents, blood transfusions, and intravenous iron, are often limited by side effects, high costs, and poor accessibility. Moringa oleifera, rich in iron, calcium, vitamin C, flavonoids, and polyphenols, exhibits hematopoietic and antioxidative properties in preclinical studies. This systematic review and meta-analysis assessed the effects of M. oleifera on hematologic parameters in chemotherapy-induced anemia models. Methods: A systematic search of PubMed, Cochrane Library, Scopus, PMC, and ProQuest (April–June 2025) was performed following PRISMA 2020 guidelines. Eligible studies investigated M. oleifera in chemotherapy- or chemically-induced anemia and reported hemoglobin (Hb), red blood cell (RBC) count, or packed cell volume (PCV). Data were analyzed using SYRCLE’s risk-of-bias tool and a random-effects model. Results: Eight preclinical studies met inclusion criteria. M. oleifera significantly increased Hb (MD= 2.97, 95% CI 1.96–3.97), RBC (MD = 0.73, 95% CI 0.14–1.31), and PCV (MD = 11.96, 95% CI 2.89–21.03). Substantial heterogeneity (I² = 67–95%) was observed. Conclusions: Moringa oleifera improved hematological parameters in preclinical CIA models. Further clinical trials are needed to confirm efficacy, safety, and optimal dosage in humans.
- 27 December 2025
- Published by CMMB-Colegiul Medicilor Municipiul Bucuresti in Medicina Moderna - Modern Medicine
- Vol. 32 (4) , 323-332
The Effect of Moringa oleifera on Hematological Parameters in Chemotherapy-Induced Anemia: A Systematic Review and Meta-analysis
Background: Chemotherapy-induced anemia (CIA) is a common complication caused by bone marrow suppression in patients receiving chemotherapy. Standard treatments, including erythropoiesisstimulating agents, blood transfusions, and intravenous iron, are often limited by side effects, high costs, and poor accessibility. Moringa oleifera, rich in iron, calcium, vitamin C, flavonoids, and polyphenols, exhibits hematopoietic and antioxidative properties in preclinical studies. This systematic review and meta-analysis assessed the effects of M. oleifera on hematologic parameters in chemotherapy-induced anemia models. Methods: A systematic search of PubMed, Cochrane Library, Scopus, PMC, and ProQuest (April–June 2025) was performed following PRISMA 2020 guidelines. Eligible studies investigated M. oleifera in chemotherapy- or chemically-induced anemia and reported hemoglobin (Hb), red blood cell (RBC) count, or packed cell volume (PCV). Data were analyzed using SYRCLE’s risk-of-bias tool and a random-effects model. Results: Eight preclinical studies met inclusion criteria. M. oleifera significantly increased Hb (MD= 2.97, 95% CI 1.96–3.97), RBC (MD = 0.73, 95% CI 0.14–1.31), and PCV (MD = 11.96, 95% CI 2.89–21.03). Substantial heterogeneity (I² = 67–95%) was observed. Conclusions: Moringa oleifera improved hematological parameters in preclinical CIA models. Further clinical trials are needed to confirm efficacy, safety, and optimal dosage in humans.
- Open Access
- 13 November 2025
- Published by Elsevier in Chemical Physics Impact
- Vol. 11
Repurposing halofuginone derivatives for osteoarthritis therapy: Structural insights, multi-target inhibition, and pharmacokinetic profiling
- 13 November 2025
- Published by Elsevier in Chemical Physics Impact
- Vol. 11
Open AccessRepurposing halofuginone derivatives for osteoarthritis therapy: Structural insights, multi-target inhibition, and pharmacokinetic profiling
- Open Access
- 1 November 2025
- Published by Garval Editorial Ltda. in Journal of Pharmacy & Pharmacognosy Research
- Vol. 13 (6) , 1978-1995
Gastroprotective effects of Zingiber officinale in rodent models of peptic ulcers: A systematic review and meta-analysis
Context: Peptic ulcer remains a significant global health concern, particularly in low-resource settings. Conventional treatments are often associated with side effects and recurrence, prompting interest in herbal therapies such as Zingiber officinale (ginger). Aims: To explore the gastroprotective efficacy of Z. officinale in preclinical models of experimentally induced peptic ulcer. Methods: Electronic databases (Scopus, ScienceDirect, and PubMed) were searched for relevant studies published between 2015 and 2024. Eligible studies included rodent models of peptic ulcer treated with Z. officinale and reporting ulcer index outcomes. Risk of bias was assessed using SYRCLE’s tool, and meta-analysis was performed using Review Manager 5.4.1 software. Standardized mean differences (SMD) with 95% confidence intervals (CI) were calculated using a random-effects model. Results: Five experimental animal studies from 2015 onwards to assess the gastroprotective effects of Z. officinale, involving 240 rodents with peptic ulcers induced via WIR stress, ethanol, HCl, or diclofenac, were included. Z. officinale, administered in various forms, significantly reduced ulcer severity compared to placebo (SMD = -5.35; 95% CI: -6.56 to -4.10; I² = 79%) and showed efficacy comparable to standard therapies (SMD = 2.88; 95% CI: 1.36 to 4.41; I² = 91) as proton pump inhibitor (PPI) and H2 blockers. Conclusions: Z. officinale exhibits significant gastroprotective activity in animal models of peptic ulcer. These findings support its potential as a candidate for further development in ulcer therapy, although standardized protocols and clinical trials are warranted.
- 1 November 2025
- Published by Garval Editorial Ltda. in Journal of Pharmacy & Pharmacognosy Research
- Vol. 13 (6) , 1978-1995
Open AccessGastroprotective effects of Zingiber officinale in rodent models of peptic ulcers: A systematic review and meta-analysis
Context: Peptic ulcer remains a significant global health concern, particularly in low-resource settings. Conventional treatments are often associated with side effects and recurrence, prompting interest in herbal therapies such as Zingiber officinale (ginger). Aims: To explore the gastroprotective efficacy of Z. officinale in preclinical models of experimentally induced peptic ulcer. Methods: Electronic databases (Scopus, ScienceDirect, and PubMed) were searched for relevant studies published between 2015 and 2024. Eligible studies included rodent models of peptic ulcer treated with Z. officinale and reporting ulcer index outcomes. Risk of bias was assessed using SYRCLE’s tool, and meta-analysis was performed using Review Manager 5.4.1 software. Standardized mean differences (SMD) with 95% confidence intervals (CI) were calculated using a random-effects model. Results: Five experimental animal studies from 2015 onwards to assess the gastroprotective effects of Z. officinale, involving 240 rodents with peptic ulcers induced via WIR stress, ethanol, HCl, or diclofenac, were included. Z. officinale, administered in various forms, significantly reduced ulcer severity compared to placebo (SMD = -5.35; 95% CI: -6.56 to -4.10; I² = 79%) and showed efficacy comparable to standard therapies (SMD = 2.88; 95% CI: 1.36 to 4.41; I² = 91) as proton pump inhibitor (PPI) and H2 blockers. Conclusions: Z. officinale exhibits significant gastroprotective activity in animal models of peptic ulcer. These findings support its potential as a candidate for further development in ulcer therapy, although standardized protocols and clinical trials are warranted.
- Open Access
- 11 September 2025
- Published by Pensoft Publishers in Pharmacia
- Vol. 72, 1-9
Magnesium supplementation improves ovarian folliculogenesis in type 1 diabetes mellitus
Introduction: Type 1 diabetes mellitus (T1DM) is associated with oxidative stress and metabolic dysfunction, contributing to impaired ovarian folliculogenesis and reproductive dysfunction. Meanwhile, magnesium plays a crucial role in improving insulin sensitivity, reducing oxidative stress, and supporting cellular functions. Objective: This study aimed to evaluate the effects of magnesium supplementation, insulin therapy, and their combination on metabolic biomarkers, oxidative stress, and ovarian folliculogenesis in streptozotocin (STZ)-induced T1DM rats. Methods: A total of 35 female Wistar rats were divided into five groups, namely P1 (control), P2 (diabetic untreated), P3 (diabetic + insulin 4 IU/200 g/day), P4 (diabetic + magnesium 300 mg/kg/day), and P5 (diabetic + insulin + magnesium). The treatments were administered for 21 days. Fasting blood glucose (FBG), serum insulin, IGF-1, HER2/neu, and malondialdehyde (MDA) levels were measured. Ovarian follicle counts and histopathological evaluations were conducted to assess folliculogenesis. Results: Magnesium (P4) and combination therapy (P5) significantly improved serum insulin levels (P4: 3.36 ± 0.46 mIU/L; P5: 4.19 ± 0.29 mIU/L; control: 4.05 ± 0.37 mIU/L), reduced MDA concentrations (P4: 0.94 ± 0.16 nmol/mL; P5: 0.97 ± 0.14 nmol/mL; control: 0.94 ± 0.30 nmol/mL), and restored IGF-1 levels (P5: 54.51 ± 4.45 ng/mL; control: 55.20 ± 9.69 ng/mL). Histopathological analysis showed significant follicular restoration in P5, with counts of primary, secondary, and Graafian follicles approaching normal levels (P5: 18.57 ± 2.37; control: 22.14 ± 1.35). Conclusion: Magnesium supplementation, particularly in combination with insulin, reduced oxidative stress, restored metabolic biomarkers, and improved ovarian folliculogenesis in T1DM. This combination therapy offers a promising approach for managing diabetes-related reproductive dysfunction.
- 11 September 2025
- Published by Pensoft Publishers in Pharmacia
- Vol. 72, 1-9
Open AccessMagnesium supplementation improves ovarian folliculogenesis in type 1 diabetes mellitus
Introduction: Type 1 diabetes mellitus (T1DM) is associated with oxidative stress and metabolic dysfunction, contributing to impaired ovarian folliculogenesis and reproductive dysfunction. Meanwhile, magnesium plays a crucial role in improving insulin sensitivity, reducing oxidative stress, and supporting cellular functions. Objective: This study aimed to evaluate the effects of magnesium supplementation, insulin therapy, and their combination on metabolic biomarkers, oxidative stress, and ovarian folliculogenesis in streptozotocin (STZ)-induced T1DM rats. Methods: A total of 35 female Wistar rats were divided into five groups, namely P1 (control), P2 (diabetic untreated), P3 (diabetic + insulin 4 IU/200 g/day), P4 (diabetic + magnesium 300 mg/kg/day), and P5 (diabetic + insulin + magnesium). The treatments were administered for 21 days. Fasting blood glucose (FBG), serum insulin, IGF-1, HER2/neu, and malondialdehyde (MDA) levels were measured. Ovarian follicle counts and histopathological evaluations were conducted to assess folliculogenesis. Results: Magnesium (P4) and combination therapy (P5) significantly improved serum insulin levels (P4: 3.36 ± 0.46 mIU/L; P5: 4.19 ± 0.29 mIU/L; control: 4.05 ± 0.37 mIU/L), reduced MDA concentrations (P4: 0.94 ± 0.16 nmol/mL; P5: 0.97 ± 0.14 nmol/mL; control: 0.94 ± 0.30 nmol/mL), and restored IGF-1 levels (P5: 54.51 ± 4.45 ng/mL; control: 55.20 ± 9.69 ng/mL). Histopathological analysis showed significant follicular restoration in P5, with counts of primary, secondary, and Graafian follicles approaching normal levels (P5: 18.57 ± 2.37; control: 22.14 ± 1.35). Conclusion: Magnesium supplementation, particularly in combination with insulin, reduced oxidative stress, restored metabolic biomarkers, and improved ovarian folliculogenesis in T1DM. This combination therapy offers a promising approach for managing diabetes-related reproductive dysfunction.
- Open Access
- 1 September 2025
- Published by Garval Editorial Ltda.
- Vol. 13 (5) , 1557-1571
Bibliometric mapping of secretomes, exosomes, and extracellular vesicles in Alzheimer’s disease
Context: Alzheimer’s Disease (AD) is a neurodegenerative disorder with limited treatment options, primarily addressing symptoms without targeting underlying mechanisms. Emerging therapies involving secretomes, exosomes, and extracellular vesicles (EVs) show promise in modulating AD pathology, including amyloid-beta accumulation, tau aggregation, and neuroinflammation. Aims: To conduct a bibliometric analysis of global research on secretomes, exosomes, and EVs in AD to identify trends, key contributors, and future research directions. Methods: A bibliometric analysis was conducted using the Scopus database. A total of 988 studies were identified based on English-language and final publication-stage studies, reviews, and conference papers. The data were analyzed using Scopus tools, the bibliometrics R package (Biblioshiny), and VOSviewer to evaluate publication trends, key contributors, and keyword co-occurrence networks. Results: Research on secretomes, exosomes, and EVs in AD has grown steadily from 2003 to 2025, with a significant increase in publications since 2010. The studies span 397 sources, with an annual growth rate of 6.5% and a high average citation rate per article (65.55). Key topics included fundamental mechanisms (e.g., neuroinflammation, amyloid-beta, tauopathy), biomarker development, and therapeutic approaches. Emerging areas requiring further exploration include clinical applications (e.g., delivery systems), novel biomarkers (e.g., gut–brain axis indicators), and advanced analytical methods (e.g., machine learning, bioinformatics). Conclusions: This study reveals an expanding global interest in the role of secretomes, exosomes, and EVs in AD. It identifies significant trends and research gaps, emphasizing the need for translational efforts that bridge experimental insights and clinical applications. Future efforts should focus on translating promising findings into clinical applications while addressing underexplored topics and fostering international collaboration.
- 1 September 2025
- Published by Garval Editorial Ltda.
- Vol. 13 (5) , 1557-1571
Open AccessBibliometric mapping of secretomes, exosomes, and extracellular vesicles in Alzheimer’s disease
Context: Alzheimer’s Disease (AD) is a neurodegenerative disorder with limited treatment options, primarily addressing symptoms without targeting underlying mechanisms. Emerging therapies involving secretomes, exosomes, and extracellular vesicles (EVs) show promise in modulating AD pathology, including amyloid-beta accumulation, tau aggregation, and neuroinflammation. Aims: To conduct a bibliometric analysis of global research on secretomes, exosomes, and EVs in AD to identify trends, key contributors, and future research directions. Methods: A bibliometric analysis was conducted using the Scopus database. A total of 988 studies were identified based on English-language and final publication-stage studies, reviews, and conference papers. The data were analyzed using Scopus tools, the bibliometrics R package (Biblioshiny), and VOSviewer to evaluate publication trends, key contributors, and keyword co-occurrence networks. Results: Research on secretomes, exosomes, and EVs in AD has grown steadily from 2003 to 2025, with a significant increase in publications since 2010. The studies span 397 sources, with an annual growth rate of 6.5% and a high average citation rate per article (65.55). Key topics included fundamental mechanisms (e.g., neuroinflammation, amyloid-beta, tauopathy), biomarker development, and therapeutic approaches. Emerging areas requiring further exploration include clinical applications (e.g., delivery systems), novel biomarkers (e.g., gut–brain axis indicators), and advanced analytical methods (e.g., machine learning, bioinformatics). Conclusions: This study reveals an expanding global interest in the role of secretomes, exosomes, and EVs in AD. It identifies significant trends and research gaps, emphasizing the need for translational efforts that bridge experimental insights and clinical applications. Future efforts should focus on translating promising findings into clinical applications while addressing underexplored topics and fostering international collaboration.
- Open Access
- 11 June 2025
- Published by Innovative Research Publishing in International Journal of Innovative Research and Scientific Studies
- Vol. 8 (4) , 2481-2495
Rational design and computational screening of febrifugine analogues as selective MMP inhibitors for osteoarthritis treatment
Osteoarthritis (OA) is a degenerative joint disorder that primarily affects aging populations, resulting in progressive cartilage degradation and joint dysfunction. The pathological role of matrix metalloproteinases (MMPs), particularly MMP-1, MMP-8, and MMP-13, in extracellular matrix breakdown highlights them as attractive therapeutic targets. This study investigated the inhibitory potential of febrifugine analogs against these collagenases using molecular docking and molecular dynamics (MD) simulations. Computational methods were employed to evaluate binding affinities, stability, and pharmacokinetic profiles of the compounds. Among the tested compounds, Compound 19 exhibited the most favorable binding energies, with -118.788 kJ/mol for MMP-8, -96.532 kJ/mol for MMP-13, and -72.528 kJ/mol for MMP-1. Molecular dynamics simulations validated the stability of Compound 19 complexes over a 200 ns trajectory, as indicated by stable root mean square deviation (RMSD) and radius of gyration (Rg) values. The MM/PBSA free energy decomposition analysis revealed significant contributions from van der Waals and electrostatic interactions, further confirming the binding efficiency. Pharmacokinetic assessments showed that Compound 19 adhered to Lipinski’s rule of five, with favorable absorption, distribution, metabolism, and excretion (ADME) characteristics. These results highlight Compound 19 as a potent inhibitor with strong selectivity for MMP-8, making it a promising candidate for osteoarthritis therapy. Further experimental validation is required to confirm its efficacy and explore structure-activity relationships for improved selectivity and safety. This study underscores the potential of febrifugine-based analogs in advancing disease-modifying treatments for osteoarthritis.
- 11 June 2025
- Published by Innovative Research Publishing in International Journal of Innovative Research and Scientific Studies
- Vol. 8 (4) , 2481-2495
Open AccessRational design and computational screening of febrifugine analogues as selective MMP inhibitors for osteoarthritis treatment
Osteoarthritis (OA) is a degenerative joint disorder that primarily affects aging populations, resulting in progressive cartilage degradation and joint dysfunction. The pathological role of matrix metalloproteinases (MMPs), particularly MMP-1, MMP-8, and MMP-13, in extracellular matrix breakdown highlights them as attractive therapeutic targets. This study investigated the inhibitory potential of febrifugine analogs against these collagenases using molecular docking and molecular dynamics (MD) simulations. Computational methods were employed to evaluate binding affinities, stability, and pharmacokinetic profiles of the compounds. Among the tested compounds, Compound 19 exhibited the most favorable binding energies, with -118.788 kJ/mol for MMP-8, -96.532 kJ/mol for MMP-13, and -72.528 kJ/mol for MMP-1. Molecular dynamics simulations validated the stability of Compound 19 complexes over a 200 ns trajectory, as indicated by stable root mean square deviation (RMSD) and radius of gyration (Rg) values. The MM/PBSA free energy decomposition analysis revealed significant contributions from van der Waals and electrostatic interactions, further confirming the binding efficiency. Pharmacokinetic assessments showed that Compound 19 adhered to Lipinski’s rule of five, with favorable absorption, distribution, metabolism, and excretion (ADME) characteristics. These results highlight Compound 19 as a potent inhibitor with strong selectivity for MMP-8, making it a promising candidate for osteoarthritis therapy. Further experimental validation is required to confirm its efficacy and explore structure-activity relationships for improved selectivity and safety. This study underscores the potential of febrifugine-based analogs in advancing disease-modifying treatments for osteoarthritis.
- Open Access
- 5 June 2025
- Published by Pensoft Publishers in Pharmacia
- Vol. 72, 1-10
Effects of Alpinia galanga and prednisone on biomarkers and fetal development in asthmatic pregnancy: A rat model study
Background: The combination of asthma and pregnancy worsens placental function and fetal growth, with severe asthma increasing the risk of maternal and fetal hypoxia. Maternal hypoxia disrupts placental blood flow, reducing oxygen and nutrient transport to the fetus and affecting birth weight. Current asthma treatments remain costly and may cause side effects, leading pregnant women to seek alternatives. This study evaluated the effects of Alpinia galanga extract (EAG) and prednisone in pregnant rats with ovalbumin-induced asthma. Methods: Thirty-five pregnant asthmatic Wistar rats were divided into five groups and treated for 19 days. Results: The combination of Alpinia galanga extract and prednisone significantly reduced IL-5 levels by 54% (p < 0.001) and MDA levels by 70% (p < 0.001), while PlGF levels increased by 36% (p < 0.001), and microvessel density improved by 123% (p < 0.001), with fetal weight 4.3 times higher (p < 0.001) in the combination group compared to the untreated asthmatic group, indicating enhanced placental function and fetal growth. Conclusion: These results suggest that EAG shows potential as a complementary therapy based on preclinical outcomes. These findings may inform future preclinical investigations on adjunct therapies for asthma during pregnancy.
- 5 June 2025
- Published by Pensoft Publishers in Pharmacia
- Vol. 72, 1-10
Open AccessEffects of Alpinia galanga and prednisone on biomarkers and fetal development in asthmatic pregnancy: A rat model study
Background: The combination of asthma and pregnancy worsens placental function and fetal growth, with severe asthma increasing the risk of maternal and fetal hypoxia. Maternal hypoxia disrupts placental blood flow, reducing oxygen and nutrient transport to the fetus and affecting birth weight. Current asthma treatments remain costly and may cause side effects, leading pregnant women to seek alternatives. This study evaluated the effects of Alpinia galanga extract (EAG) and prednisone in pregnant rats with ovalbumin-induced asthma. Methods: Thirty-five pregnant asthmatic Wistar rats were divided into five groups and treated for 19 days. Results: The combination of Alpinia galanga extract and prednisone significantly reduced IL-5 levels by 54% (p < 0.001) and MDA levels by 70% (p < 0.001), while PlGF levels increased by 36% (p < 0.001), and microvessel density improved by 123% (p < 0.001), with fetal weight 4.3 times higher (p < 0.001) in the combination group compared to the untreated asthmatic group, indicating enhanced placental function and fetal growth. Conclusion: These results suggest that EAG shows potential as a complementary therapy based on preclinical outcomes. These findings may inform future preclinical investigations on adjunct therapies for asthma during pregnancy.